Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN – Get Free Report) was the recipient of a significant growth in short interest in the month of October. As of October 15th, there was short interest totalling 142,900 shares, a growth of 20.5% from the September 30th total of 118,600 shares. Based on an average daily trading volume, of 65,300 shares, the days-to-cover ratio is currently 2.2 days.
Eledon Pharmaceuticals Stock Performance
NASDAQ:ELDN traded up $0.60 during mid-day trading on Wednesday, hitting $4.19. The company had a trading volume of 3,157,325 shares, compared to its average volume of 180,134. The firm has a market cap of $166.16 million, a P/E ratio of -2.05 and a beta of 0.88. The business’s fifty day moving average is $2.79 and its two-hundred day moving average is $2.66. Eledon Pharmaceuticals has a fifty-two week low of $1.07 and a fifty-two week high of $4.41.
Eledon Pharmaceuticals (NASDAQ:ELDN – Get Free Report) last released its quarterly earnings results on Monday, August 19th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.01). Equities analysts forecast that Eledon Pharmaceuticals will post -1.52 earnings per share for the current year.
Institutional Investors Weigh In On Eledon Pharmaceuticals
About Eledon Pharmaceuticals
Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).
See Also
- Five stocks we like better than Eledon Pharmaceuticals
- What is Short Interest? How to Use It
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- NYSE Stocks Give Investors a Variety of Quality OptionsĀ
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- Best Aerospace Stocks Investing
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for Eledon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eledon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.